The goal of the Career Development Program of the M. D. Anderson Cancer Center Prostate SPORE is to develop a cadre of investigators dedicated to translational studies in human prostate cancer. The program will (1) recruit innovative entry-level scientists into the Prostate SPORE to enhance its overall translational research capability and bring new techniques and talent to our SPORE program, (2) help these individuals develop the intellectual and technical skills required to be productive investigators in translational prostate cancer research, and (3) teach these individuals basic principles of cancer biology not commonly included in clinical training or PhD degree programs. The unique educational environment that exists at M. D. Anderson will ensure that these goals will be met. At least three Career Development awardees will be selected annually from qualified candidates within and outside M. D. Anderson Cancer Center. Awardees will be selected from the pool of candidates who respond to a SPORE solicitation based on objective criteria established by the Program Director and Co-Director in collaboration with the Principal Investigator and Co- Principal Investigator. Applications will be solicited and reviewed annually, and announcements for applications will be published in appropriate journals and on the SPORE web site as well as mailed to selected academic centers. The awardees'mentors have been selected from a large, diverse group of laboratory scientists and clinicians at M. D. Anderson based on their interest in translational science and skill as educators. The mentorship training will include principles of cancer biology, scientific methods, statistical analysis, biomedical communications, and strategies necessary to become successful in translational prostate cancer research. The program will be evaluated annually, and modifications in the selection process or training will be made when appropriate. Nine Career Development awards were funded by the initial SPORE in Prostate Cancer. Investigators receiving Career Development Awards reported 96 publications. A total of 25 externally reviewed grants were funded. Of note, one investigator (Dr. Jeri Kim) is a collaborator in Project 5 and the Specimen Core in this new M. D. Anderson Cancer Center Prostate SPORE proposal, reflecting the important role of the Career Development Program in identifying investigators with the potential to make significant contributions in translational prostate cancer research.
The goal of the Career Development Program of the M. D. Anderson Cancer Center Prostate SPORE is to develop a cadre of investigators dedicated to translational studies in human prostate cancer by recruiting innovative entry-level scientists to enhance, the SPORE's overall translational research capability, helping these individuals develop intellectual and technical skills required to be productive investigators, and teaching these individuals basic principles of cancer biology.
|Luo, Yong; Azad, Abul Kalam; Karanika, Styliani et al. (2017) Enzalutamide and CXCR7 inhibitor Combination Treatment Suppresses Cell Growth and Angiogenic Signaling in Castration-Resistant Prostate Cancer Models. Int J Cancer :|
|Lin, Song-Chang; Lee, Yu-Chen; Yu, Guoyu et al. (2017) Endothelial-to-Osteoblast Conversion Generates Osteoblastic Metastasis of Prostate Cancer. Dev Cell 41:467-480.e3|
|Gao, Jianjun; Ward, John F; Pettaway, Curtis A et al. (2017) VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med 23:551-555|
|Yu, Kai-Jie; Li, Jeffrey K; Lee, Yu-Chen et al. (2017) Cabozantinib-induced osteoblast secretome promotes survival and migration of metastatic prostate cancer cells in bone. Oncotarget 8:74987-75006|
|Tu, Huakang; Gu, Jian; Meng, Qing H et al. (2017) Low serum testosterone is associated with tumor aggressiveness and poor prognosis in prostate cancer. Oncol Lett 13:1949-1957|
|Gökce, Mehmet I; Wang, Xuemei; Frost, Jacqueline et al. (2017) Informed decision making before prostate-specific antigen screening: Initial results using the American Cancer Society (ACS) Decision Aid (DA) among medically underserved men. Cancer 123:583-591|
|Karanika, Styliani; Karantanos, Theodoros; Li, Likun et al. (2017) Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling. Cell Rep 18:1970-1981|
|Saha, Achinto; Blando, Jorge; Fernandez, Irina et al. (2016) Linneg Sca-1high CD49fhigh prostate cancer cells derived from the Hi-Myc mouse model are tumor-initiating cells with basal-epithelial characteristics and differentiation potential in vitro and in vivo. Oncotarget 7:25194-207|
|Fong, Eliza L S; Wan, Xinhai; Yang, Jun et al. (2016) A 3D in vitro model of patient-derived prostate cancer xenograft for controlled interrogation of in vivo tumor-stromal interactions. Biomaterials 77:164-72|
|Subudhi, Sumit K; Aparicio, Ana; Gao, Jianjun et al. (2016) Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proc Natl Acad Sci U S A 113:11919-11924|
Showing the most recent 10 out of 198 publications